Na+ currents in cardioprotection: Better to be late

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4149-4160

  Le Grand, Bruno ^a   Pignier, Christophe ^a   Létienne, Robert ^a   Colpaert, Francis ^b   Cuisiat, Florence ^a   Rolland, Françoise ^a   Mas, Agnes ^a   Borras, Maud ^a   Vacher, Bernard ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Toulouse ISTMT 2 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO N [3 [(2 HYDROXY 3 METHYLPHENYL)THIO] 2 METHYLPROPYL] 2H 1,5 BENZOXATHIEPIN 3 AMINE; AMINE; BENZENE DERIVATIVE; CARIPORIDE; F 15741; IVABRADINE; LIDOCAINE; METHYL GROUP; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.5; THIEPIN DERIVATIVE; TROPONIN I; UNCLASSIFIED DRUG; VERATRIDINE; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; ISOLATED HEART; MALE; NONHUMAN; RAT; REPERFUSION INJURY; SODIUM CURRENT; STRUCTURE ACTIVITY RELATION; SWINE;

ANIMALS; BENZOTHIEPINS; BENZOXAZOLES; CARDIOTONIC AGENTS; CELL LINE; ELECTRIC CONDUCTIVITY; FEMALE; GUINEA PIGS; HUMANS; MALE; MYOCARDIAL INFARCTION; RATS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; TIME FACTORS;

EID: 67650727090     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900296e     Document Type: Article

References (87)

1. Le Grand, B.; Pignier, C.; Letienne, R.; Cuisiat, F.; Rolland, F.; Mas, A.; Vacher, B. Sodium Late Current Blockers in Ischemia Reperfusion: Is the Bullet Magic? J. Med. Chem. 2008, 51, 3856-3866.
2. Vacher, B.; Pignier, C; Letienne, R.; Verscheure, Y.; Le Grand, B. F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models. Br. J. Pharmacol. 2009, 156, 214-225.
3. (a) Chaitman, B. R.; Pepine, C. J.; Parker, J. O.; Skopal, J.; Chumakova, G.; Kuch, J.; Wang, W.; Skettino, S. L.; Wolff, A. A. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. J. Am. Med. Assoc. 2004, 291, 309-316.
4. (b) Hooper, J. S.; Busti, A. J.; Pechlaner, C.; Wiedermann, C.; Chaitman, B. R. Ranolazine as Add-on Therapy for Patients with Severe Chronic Angina. J. Am. Med. Assoc. 2004, 291, 1959-1960.
5. (c) Sajadieh, A. A new combination therapy in stable angina pectoris. Eur. Heart J. 2009, 30, 524-525.
6. Cannon, S. C. Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralysis. Kidney Int. 2000, 57, 772-779.
7. (a) Bennett, P. B.; Yazawa, K.; Makita, N.; George, A. L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995, 376, 683-685.
8. + channel associated with idiopathic ventricular fibrillation. Am. J. Physiol. 2001, 280, H354-H360.
9. (c) Remme, C. A.; Wilde, A. A. M.; Bezzina, C. R. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc. Med. 2008, 18, 78-87.
10. (a) Cox, J. J.; Nicholas, A. K.; Thornton, G.; Woods, C. G.; Reimann, F.; Gribble, F. M.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y.; Al-Gazali, L.; Hamamy, H.; Valente, E. M.; Gorman, S.; Williams, R.; McHale,D. P.; Wood, J. N. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444, 894-898.
11. (b) Spampanato, J.; Goldin, A. L.; Aradi, I.; Soltesz, I.; Goldin, A. L.; Kearney, J. A.; De Haan, G.; Escayg, A.; MacDonald, B. T.; Levin, S. I.; Meisler, M. H.; McEwen, D. P.; Isom, L. L.; Benna, P.; Montalenti, E.; Meisler, M. H. A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction. J. Neurosci. 2004, 24, 10022-10034.
12. (c) Abou-Khalil, B; Ge, Q.; Desai, R.; Ryther, R; Bazyk, A.; Bailey, R.; Haines, J. L.; Sutcliffe, J. S.; George, A. L. Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology 2001, 57, 2265-2272.
13. Ranolazine: N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2- methoxyphenoxy) propyl]-1-piperazineacetamide, [95635-55-5]. McCullough, P. A. Ranolazine: focusing on angina pectoris Drugs Today 2006, 42, 177-183.
14. (a) Schram, G.; Zhang, L.; Derakhchan, K.; Ehrlich, J. R.; Belardinelli, L.; Nattel, S. Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects. Br. J. Pharmacol. 2004, 142, 1300-1308.
15. (b) Antzelevitch, C; Belardinelli, L; Zygmunt, A. C.; Burashnikov, A; Di Diego, J. M.; Fish, J. M.; Cordeiro, J. M.; Thomas, G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004, 110, 904-910.
16. (c) Hasenfuss, G; Maier, L. S. Mechanism of action of the new anti-ischaemia drug ranolazine. Clin. Res. Cardiol. 2007, 97, 222-226.
17. Scirica, B. M.; Morrow, D. A. Ranolazine in patients with angina and coronary artery disease. Curr. Cardiol. Rep. 2007, 9, 272-278.
18. (a) Hale, S. L; Shryock, J. C.; Belardinelli, L.; Sweeney, M.; Kloner, R. A. J. Mol. Cell. Cardiol. 2008, 44, 954-967.
19. (b) Scirica, M.; Morrow, D. A.; Hod, H.; Murphy, S. A.; Belardinelli, L.; Hedgepeth, C. M.; Molhoek, P.; Verheugt, F. W. A.; Gersh, B. J.; McCabe, C. H.; Braunwald, E. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007, 116, 1647-1652.
20. (a) Makielski, J. C.; Valdivia, C. R. Ranolazine and late cardiac sodium current: a therapeutic target for angina, arrhythmia and more? Br. J. Pharmacol. 2006, 148, 16-24.
21. (b) Newby, L. K.; Peterson, E. D. Does Ranolazine Have a Place in the Treatment of Acute Coronary Syndromes? J. Am. Med. Assoc. 2007, 297, 1823-1825.
22. (a) Rosamond, W.; Flegal, K.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S. M.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lloyd-Jones, D.; McDermott, M.; Meigs, J.; Moy; Nichol, G.; O'Donnell, C.; Roger, V.; Sorlie, P.; Steinberger, J.; Thom, T.; Wilson, M.; Hong Heart disease and stroke statistics, 2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117, E25-E146.
23. (b) Hearse, D. J.; Yellon, D. M.; Downey, J. M. Can beta blockers limit myocardial infarct size? Eur. Heart J. 1986, 7, 925-30.
24. Kaczorowski, G. J.; McManus, O. B.; Priest, B. T.; Garcia, M. L. Ion channels as drug targets: The next GPCRs. J. Gen. Physiol. 2008, 131, 399-405.
25. (a) Karmazyn, M.; Kilic, A.; Javadov, S. The role of NHE-1 in myocardial hypertrophy and remodelling. J. Mol. Cell. Cardiol. 2008, 44, 647-653.
26. + concentration during reperfusion is much more disputed.
27. (a) Silverman, H. S.; Stern, M. D. Ionic basis of ischaemic cardiac injury: insights from cellular studies. Cardiovasc. Res. 1994, 28, 581-597.
28. (b) Shryock, J. C.; Belardinelli, L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br. J. Pharmacol. 2008, 153, 1128-1132.
29. (c) Baetz, D.; Bernard, M.; Pinet, C.; Tamarerille, S.; Chattou, S.; El Banani, H.; Coulombe, A.; Feuvray, D. Different pathways for sodium entry in cardiac cells during ischaemia and early reperfusion. Mol. Cell. Biochem. 2003, 242, 115-120.
30. (a) Andreadou, I.; Iliodromitis, E. K.; Koufaki, M.; Farmakis, D.; Tsotinis, A.; Kremastinos, D. Th. Alternative Pharmacological Interventions that Limit Myocardial Infarction. Curr. Med. Chem. 2008, 15, 3204-3213.
31. (b) Liem, D. A.; Honda, H. M.; Zhang, J.; Woo, D.; Ping, P. Past and present course of cardioprotection against ischemia-reperfusion injury. J. Appl. Physiol. 2007, 103, 2129-2136.
32. (c) Morrow, D. A.; Scirica, B. M.; Karwatowska-Prokopczuk, E.; Murphy, S. A.; Budaj, A.; Varshavsky, S.; Wolff, A.; Skene, A.; McCabe, C. H.; Braunwald, E. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. J. Am. Med. Assoc. 2007, 297, 1775-1783.
33. (d) Xu, Z.; Mueller, R. A.; Park, S.-S.; Boysen, P. G.; Cohen, M. V.; Downey, J. M. Cardioprotection with adenosine A2 receptor activation at reperfusion. J. Cardiovasc. Pharmacol. 2005, 46, 794-802.
34. (a) Mancuso, A. J.; Brownfain, D. S.; Swern, D. Structure of the dimethyl sulfoxide-oxalyl chloride reaction product. Oxidation of heteroaromatic and diverse alcohols to carbonyl compounds. J. Org. Chem. 1979, 44, 4148-4150.
35. (b) Evans, D. A.; Ng, H. P.; Rieger, D. Total Synthesis of the Macrolide Antibiotic Rutamycin B. J. Am. Chem. Soc. 1993, 115, 11446-11459.
36. Vacher, B.; Brunel, Y.; Castan-Cuisiat, F. An improved process for the preparation of benzoxathiepines and their intermediates Pierre Fabre Medicament. Patent WO 2005103027, 2005.
37. Abdel-Magid, A. F.; Mehrman, S. J. A Review on the Use of Sodium Triacetoxyborohydride in the Reductive Amination of Ketones and Aldehydes. Org. Process Res. Dev. 2006, 10, 971-1031.
38. (a) Yoon, N. M.; Gyoung, Y. S. Reaction of diisobutylaluminum hydride with selected organic compounds containing representative functional groups. J. Org. Chem. 1985, 50, 2443-2450.
39. 2NR and DIBAL-H-HNR1R2·HCl complexes for efficient conversion of lactones and esters to amides. Tetrahedron Lett. 2001, 42, 9039-9041.
40. 2O. Bull. Korean Chem. Soc. 2004, 25, 407-409.
41. Jois, Y. H. R.; Gibson, H. W. Difunctional heterocycles: a convenient one pot synthesis of novel bis(benzoxazoles) from bis(o-aminophenols). J. Heterocycl. Chem. 1992, 29, 1365-1368.
42. (a) 2-Methoxy-3-methylbenzenethiol 3c, [25674-52-6]: Cabiddu, S.; Maccioni, A.; Secci, M. Cleavage of the ether bond. IV. Action of organometallic compounds on 2,2-dimethyl-1,3-oxathiolane and on some 1,3-benzoxathiole and 1-methoxy-2-alkylthio aromatic derivatives. Gazz. Chim. Ital. 1969, 99, 1095-1106.
43. (b) Shah, M. S.; Bhatt, C. T.; Kanga, D. D. Thiols derived from o-, m-, and p-methoxytoluenes and -benzoic acids. J. Chem. Soc. 1933, 1375-1381.
44. 2-Hydroxy-3-methylbenzenethiol 3d, [25674-50-4]: Yoshida, Y.; Ogura, M.; Tanabe, Y. Regiocontrolled carbonylsulfanylations at ortho-position of phenols and at ·alpha ·-position of ketones using chlorocarbonylsulfenyl chloride. Heterocycles 1999, 50, 681-692.
45. 2-Hydroxy-3-ethylbenzenethiol 3e, [470454-34-3]; 2-hydroxy-3-isopropylbenzenethiol 3f, [470454-47-8] and 2,3-dihydrobenzofuran-7-thiol 3o, [470453-91-9]: Vacher, B.; Castant-Cuisiat, F.; John, G.; Legrand, B. (Pierre Fabre Medicament). Patent WO 2002081464, 2002.
46. (a) 2-Amino-3-methylbenzenethiol 3l, [76462-17-4]: Thomas, L.; Gupta, A.; Gupta, V. One-pot synthesis of 3,5-dimethyl/3,7-dimethyl-4H-1, 4-benzothiazines. Heterocycl. Commun. 2002, 8, 169-172.
47. (b) Inoue, H.; Konda, M.; Hashiyama, T.; Otsuka, H.; Watanabe, A.; Gaino, M.; Takahashi, K.; Date, T.; Okamura, K.; Takeda, M.; Narita, H.; Murata, S.; Odawara, A.; Sasaki, H.; Nagao, T. Synthesis and biological evaluation of alkyl, alkoxy, alkylthio, or amino-substituted 2,3-dihydro-1,5-benzothiazepin-4 (5H)-ones. Chem. Pharm. Bull. 1997, 45, 1008-1026.
48. (c) Gupta, R. R.; Ojha, K. G.; Kumar, M. Studies on phenothiazines. Part 7. Synthesis of 3-substituted 2-aminobenzenethiols and their conversion into phenothiazines. J. Heterocycl. Chem. 1980, 17, 1325-1327.
49. (a) 2-Amino-3-methoxybenzenethiol 3m, [73931-64-3]: Kajino,M.; Mizuno,K.; Tawada,H.; Shibouta, Y.; Nishikawa, K.;Meguro, K. Synthesis and biological activities of new 1,4-benzothiazine derivatives. Chem. Pharm. Bull. 1991, 39, 2888-2895.
50. (b) Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2- benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J. Med. Chem. 1991, 34, 108-122.
51. (c) Chedekel, M. R.; Sharp, D. E.; Jeffery,G.A. Synthesis of o-aminothiophenols. Synth. Commun. 1980, 10, 167-173.
52. 2-amino-3-fluorobenzenethiol 3n, [73628-29-2]: Gupta, R. R.; Kumar, R. Synthesis of 2-amino-3-fluorobenzenethiol and its conversion into different heterocycles. Synth. Commun. 1987, 17, 229-240.
53. (a) Lazdunski, M.; Renaud, J. F. The action of cardiotoxins on cardiac plasma membranes. Annu. Rev. Physiol. 1982, 44, 463-473.
54. (b) Wermelskirchen, D.; Wilffert, B.; Peters, T. Veratridine-induced intoxication: an in vitro model for the characterization of anti-ischemic compounds? J. Basic Clin. Physiol. Pharmacol. 1992, 3, 293-321.
55. Pignier, C.; Revenaz, C.; Rauly-Lestienne, I.; Cussac, D.; Delhon, A.; Gardette, J.; Le Grand, B. Direct protective effects of polyunsaturated fatty acids, DHA and EPA, against activation of cardiac late sodium current: a mechanism for ischemia selectivity. Basic Res. Cardiol. 2007, 102, 553-564.
56. CaT. No significant interaction of 2d was detected against an extensive panel of GPCRs, uptake sites, enzymes, transporters, and exchangers.
57. Le Grand, B.; Marty, A.; Vieu, S.; Talmant, J. M.; John, G. W. Veratridine-induced tetanic contracture of the rat isolated left atrium. Evidence for novel direct protective effects of prazosin and WB4101. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993, 348, 184-190.
58. + current blockers. Am. J. Physiol. 1995, 269, H533-H540.
59. See Supporting Information.
60. Saint, D A. The cardiac persistent sodium current: an appealing therapeutic target? Br. J. Pharmacol. 2008, 153, 1133-1142.
61. Letienne, R.; Bel, L.; Bessac, A.-M.; Denais, D.; Degryse, A.-D.; John, G. W.; Le Grand, B. Cardioprotection of cariporide evaluated by plasma myoglobin and troponin I in myocardial infarction in pigs. Fundam. Clin. Pharmacol. 2006, 20, 105-113.
62. (a) The size of the necrotic zone no longer progresses beyond 48 h; see : Bohle, R. M.; Pich, S.; Klein, H. H. Modulation of the inflammatory response in experimental myocardial infarction. Eur. Heart J. 1991, Vol. 12, 28-31.
63. (b) Tissier, R.; Souktani, R.; Bruneval, P.; Giudicelli, J.-F.; Berdeaux, A.; Ghaleh, B. Adenosine A1-receptor induced late preconditioning and myocardial infarction: reperfusion duration is critical. Am. J. Physiol. 2002, 283, H38-H43.
64. + exchanger: An emerging therapeutic target in cardiovascular disorders.Drugs Today 2000, 36, 793-802.
65. + exchange inhibition by cariporide on death and nonfatal myocardial infarction in patients undergoing coronary artery bypass graft surgery: the Expedition study. Circulation 2003, 108, 2723.
66. (b) Mentzer, R. M.; Bartels, C.; Bolli, R.; Boyce, S.; Buckberg, G. D.; Chaitman, B.; Haverich, A.; Knight, J.; Menasche, P.; Myers, M L.; Nicolau, J.; Simoons, M.; Thulin, L.; Weisel, R. D. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann. Thorac. Surg. 2008, 85, 1261-1270.
67. Lidocaine: 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide, [137-58-6] is a class Ib antiarrhythmic; see: Howe, J. P.; Fee, J. P. H. Local anaesthetics. Pharmacol. Anaesthesiol. 2005, 79-92.
68. (a) Kim, S. Y.; Benowitz, N. L. poisoning due to class IA antiarrrhythmic drugs. Drug Safety 1990, 5, 393-420.
69. (b) MacMahon, S.; Collins, R.; Peto, R.; Koster, R. W.; Yusuf, S. Effects of prophylactic lidocaine in suspected acute myocadial infarction: an overview of results from randomized controlled trials. J. Am. Med. Assoc. 1988, 260, 1910-1916.
70. (c) Teo, K.; Yusuf, S.; Furberg, C. Effect of prophylactic antiarrhthmic drug therapy on post-myocardial infarction mortality. Eur. Heart J. 1992, 13 (Abst. Suppl.), 224.
71. Ivabradine: 7,8-dimethoxy-3-(3-(((1S)(4,5- dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4, 5-tetrahydro-2H-benzazepin-2-one hydrochloride [155974-00-8]: Tardif, J. -C. Ivabradine: If inhibition in the management of stable angina pectoris and other cardiovascular diseases. Drugs Today 2008, 44, 171-181.
72. Heusch, G.; Skyschally, A.; Gres, P.; van Caster, P.; Schilawa, D.; Schulz, R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur. Heart J. 2008, 29, 2265-2275.
73. The area at risk was similar (ca. 40-45%) in all experimental groups.
74. Afull dose-response for cardioprotection with 2d will be disclosed in due course.
75. (a) Troponin I is taken as a specific marker of myocardial cell damage; see : Hartmann, F.; Kampmann, M.; Frey, N.; Mueller-Bardorff, M.; Katus, H. A. Biochemical markers in the diagnosis of coronary artery disease. Eur. Heart J. 1998, 19, N2-N7.
76. (b) Hamm, C. W.; Braunwald, E. A classification of unstable angina revisited. Circulation 2000, 102, 118-122.
77. (c) Hasdai, D.; Battler, A.; Behar, S.; Boyko, V.; Danchin, N.; Bassand, J.-P.; Hasdai, D. Cardiac biomarkers and acute coronary syndromes - The Euro Heart Survey of Acute Coronary Syndromes experience. Eur. Heart J. 2003, 24, 1189-1194.
78. (d) Horwich, T. B.; Patel, J.; MacLellan, W. R.; Fonarow, G. C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003, 108, 833-838.
79. (e) Sundstrom, J.; Ingelsson, E.; Berglund, L.; Zethelius, B.; Lind, L.; Venge, P.; Arnlov, J. Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur. Heart J. 2009, 30, 773-781.
80. This delay of 6 h corresponds to the peak of troponin I release.
81. In the case of cariporide, solubility problem appears beyond the dose of 2.5 mg/kg. In the case of lidocaine, hemodynamic effects become prohibitory. For ivabradine, bradycardia becomes limiting above 1.25 mg/kg.
82. Hoefer, I. E.; Piek, J. J.; Pasterkamp, G. Pharmaceutical interventions to influence arteriogenesis: new concepts to treat ischemic heart disease. Curr. Med. Chem. 2006, 13, 979-987.
83. (a) Theroux, P.; Chaitman, B. R.; Danchin, N.; Erhardt, L.; Meinertz, T.; Schroeder, J. S.; Tognoni, G.; White, H. D.; Willerson, J. T.; Jessel, A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 2000, 102, 3032-3038.
84. (b) Winkelmann, B. R. American Heart Association scientific sessions. Expert Opin. Invest. Drugs 2004, 13, 435-445.
85. + exchange inhibitors cariporide mesylate and (3-methanesulfonyl-4-piperidino-benzoyl) guanidine methanesulfonate. Arzneim.-Forsch. 1997, 47, 1204-1207.
86. Peglion, J. L.; Vian, J.; Vilaine, J. P.; Villeneuve, N.; Janiak, P.; Bidouard, J. P.; Adir et Compagnie. FR 2 681 862, 1993.
87. Tamareille, S.; Le Grand, B.; John, G. W.; Feuvray, D.; Coulombe, A.; Anti-ischemic compound, K. C. 12291 prevents diastolic contracture in isolated atria by blockade of voltage-gated sodium channels. J. Cardiovasc. Pharmacol. 2002, 40, 346-355.